Randomized trial demonstrates thymoquinone reduces acute kidney injury in mice, indicating its potential therapeutic role.
This study aimed to investigate the protective effects of thymoquinone on lipopolysaccharide (LPS)-induced AKI in mice by assessing oxidative stress, inflammatory mediators, pyroptosis factors, and renal function markers via modulation of oxidative stress and pyroptosis pathways. Materials and Methods: Thirty-two male C57BL/6 mice (20-25 g) were randomized into four groups: control, LPS, and two LPS groups treated with thymoquinone solubilized in Cremophor (1 or 10 mg/kg). AKI was induced by intraperitoneal injection of LPS (10 mg/kg). After 24 hr, blood samples were collected for blood urea nitrogen (BUN), cystatin C, and serum creatinine assays. Kidney homogenates were analyzed for malondialdehyde (MDA), superoxide dismutase (SOD), nitrite, interleukin-6 (IL-6), nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3), and caspase-1 levels. Conclusion: Thymoquinone effectively attenuates LPS-induced AKI, likely by reducing oxidative stress, inhibiting pyroptosis and inflammation, and enhancing antioxidant defenses.
No takes yet. Share an insight, caveat, or question.
Izadi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: